Systematic dissection of transcriptional regulatory networks by genome-scale and single-cell CRISPR screens.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
07 2021
Historique:
received: 04 11 2020
accepted: 21 05 2021
entrez: 3 7 2021
pubmed: 4 7 2021
medline: 9 4 2022
Statut: epublish

Résumé

Millions of putative transcriptional regulatory elements (TREs) have been cataloged in the human genome, yet their functional relevance in specific pathophysiological settings remains to be determined. This is critical to understand how oncogenic transcription factors (TFs) engage specific TREs to impose transcriptional programs underlying malignant phenotypes. Here, we combine cutting edge CRISPR screens and epigenomic profiling to functionally survey ≈15,000 TREs engaged by estrogen receptor (ER). We show that ER exerts its oncogenic role in breast cancer by engaging TREs enriched in GATA3, TFAP2C, and H3K27Ac signal. These TREs control critical downstream TFs, among which TFAP2C plays an essential role in ER-driven cell proliferation. Together, our work reveals novel insights into a critical oncogenic transcription program and provides a framework to map regulatory networks, enabling to dissect the function of the noncoding genome of cancer cells.

Identifiants

pubmed: 34215580
pii: 7/27/eabf5733
doi: 10.1126/sciadv.abf5733
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Auteurs

Rui Lopes (R)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland. rui.lopes@novartis.com giorgio.galli@novartis.com.

Kathleen Sprouffske (K)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Caibin Sheng (C)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Esther C H Uijttewaal (ECH)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Adriana Emma Wesdorp (AE)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Jan Dahinden (J)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Simon Wengert (S)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Juan Diaz-Miyar (J)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Umut Yildiz (U)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Melusine Bleu (M)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Verena Apfel (V)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Fanny Mermet-Meillon (F)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Rok Krese (R)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Mathias Eder (M)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

André Vidas Olsen (AV)

Biotech Research and Innovation Centre (BRIC), The Finsen Laboratory, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Philipp Hoppe (P)

Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Judith Knehr (J)

Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Walter Carbone (W)

Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Rachel Cuttat (R)

Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Annick Waldt (A)

Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Marc Altorfer (M)

Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Ulrike Naumann (U)

Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Joachim Weischenfeldt (J)

Biotech Research and Innovation Centre (BRIC), The Finsen Laboratory, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Antoine deWeck (A)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Audrey Kauffmann (A)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Guglielmo Roma (G)

Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Dirk Schübeler (D)

Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Faculty of Sciences, University of Basel, Basel, Switzerland.

Giorgio G Galli (GG)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland. rui.lopes@novartis.com giorgio.galli@novartis.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH